Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.45 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4767716 | 0.98 | HPGD (0.68) | HPGDALDH1A1TSHRSMN1; SMN2LMNA | |
| SCHEMBL19612780 | 0.84 | HPGD (1.00) | HPGDALDH1A1TSHRSMN1; SMN2LMNA | |
| SCHEMBL20186941 | 0.84 | HPGD (1.00) | HPGDALDH1A1TSHRSMN1; SMN2LMNA | |
| SCHEMBL18228450 | 0.84 | HPGD (1.00) | HPGDALDH1A1TSHRSMN1; SMN2LMNA | |
| SCHEMBL3504308 | 0.84 | HPGD (1.00) | HPGDALDH1A1TSHRSMN1; SMN2LMNA | |
| SCHEMBL16992039 | 0.84 | HPGD (1.00) | HPGDALDH1A1TSHRSMN1; SMN2LMNA | |
| SCHEMBL5217652 | 0.83 | ALDH1A1 (0.72) | HPGDALDH1A1TSHRSMN1; SMN2LMNA | |
| SCHEMBL3695372 | 0.82 | ALDH1A1 (0.86) | HPGDALDH1A1TSHRSMN1; SMN2LMNA | |
| SCHEMBL2386976 | 0.82 | ALDH1A1 (0.86) | HPGDALDH1A1TSHRSMN1; SMN2LMNA | |
| SCHEMBL1826063 | 0.82 | ALDH1A1 (0.86) | HPGDALDH1A1TSHRSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9334269-B2 | Carboxamides as inhibitors of voltage-gated sodium channels | AMGEN INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2536689-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | Amgen Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011103196-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | AMGEN INC. (US) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | CACNA1B, SCN1A, CACNA1I | HPGD 1468/4885ALDH1A1 3255/4885TSHR 4164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.